JCCC encompasses an extensive matrix of laboratory, clinical and population research and clinical care facilities within the Los Angeles metropolitan area. Rather than striving for a centralized cancer center presence, we believe science has evolved to the point where it is feasible and preferable for us to embrace the rich academic environment throughout the entire UCLA campus. Our partnerships with engineering and chemistry, the Molecular Biology Institute, the Broad Stem Cell Research Center and the California Nanosystems Institute, combined with our newly formalized affiliation with Caltech, have made us stronger and more successful in this time of great opportunity in cancer research. In this section, we first describe the Louis Factor Health Sciences Building, which serves as the JCCC's administrative and research focal point. We then summarize the research facilities that are of greatest relevance to the JCCC, beyond traditional department-based laboratory space within the School of Medicine, College of Letters and Science, and School of Engineering. Next, we describe hospitals and clinical facilities that support the clinical and clinical research missions of the JCCC. Finally, we describe other key facilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016042-39
Application #
8635454
Study Section
Subcommittee G - Education (NCI)
Project Start
1996-12-01
Project End
2018-11-30
Budget Start
2014-03-07
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$341,180
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Li, Gang; Lu, Xuyang (2015) A Bayesian approach for instrumental variable analysis with censored time-to-event outcome. Stat Med 34:664-84
Epeldegui, Marta; Blom, Bianca; Uittenbogaart, Christel H (2015) BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur J Immunol 45:728-37
Bower, Julienne E; Crosswell, Alexandra D; Stanton, Annette L et al. (2015) Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 121:1231-40
Arensman, Michael D; Telesca, Donatello; Lay, Anna R et al. (2014) The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13:2303-14
Li, Keyu; Tavaré, Richard; Zettlitz, Kirstin A et al. (2014) Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther 13:2607-17
Ke, Ruian; Loverdo, Claude; Qi, Hangfei et al. (2014) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 69:724-7
Fu, Maoyong; Maresh, Erin L; Helguera, Gustavo F et al. (2014) Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13:902-15
Leoh, Lai Sum; Morizono, Kouki; Kershaw, Kathleen M et al. (2014) Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med 16:11-27
Tong, Maomeng; McHardy, Ian; Ruegger, Paul et al. (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 8:2193-206
De Azambuja, Katherine; Barman, Provabati; Toyama, Joy et al. (2014) Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo 28:761-7

Showing the most recent 10 out of 192 publications